New treatment for hearing loss caused by loud noise
eiF2B Activators to Treat Noise-Induced Hearing Loss
This study is testing a new treatment for people with noise-induced hearing loss, especially those who have been around loud sounds, by using a special medicine that targets a specific process in our cells to help improve their hearing.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Jacaranda Biosciences, INC. NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11066188 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapy to treat noise-induced hearing loss (NIHL), which is a prevalent condition affecting many individuals, particularly those exposed to loud environments. The approach involves a small molecule therapeutic that targets a specific cellular pathway known as the Unfolded Protein Response (UPR), which has not been previously explored for this condition. The research aims to advance this treatment through preclinical development, potentially offering a new solution for those suffering from NIHL. By addressing a significant public health issue, this research seeks to improve the quality of life for affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced hearing loss due to exposure to loud noises, such as those in construction, military, or recreational settings.
Not a fit: Patients with hearing loss due to non-noise-related factors, such as age-related hearing loss or genetic conditions, may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide an effective treatment option for individuals suffering from noise-induced hearing loss.
How similar studies have performed: While noise-induced hearing loss is a common issue, this specific approach targeting the UPR pathway is novel and has not been extensively tested in prior research.
Where this research is happening
San Francisco, United States
- Jacaranda Biosciences, INC. — San Francisco, United States (Active)
Researchers
- Principal investigator: Dahl, Russell — Jacaranda Biosciences, INC.
- Study coordinator: Dahl, Russell
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.